MINDBIO THERAPEUTICS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.05 CAD | +11.11% |
|
-.--% | +100.00% |
MindBio Therapeutics Corp. is a biotechnology company. The Company is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. It has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. It has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The Company invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +100.00% | 4.88M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- MBIO Stock
- News MindBio Therapeutics Corp.
- MindBio Beginning Landmark Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
